Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

FDA approves Novartis’ Pluvicto for prostate cancer

FDA approves Novartis’ Pluvicto for prostate cancer

Novartis has announced that it has received approval from the US Food and Drug Administration (FDA) for Pluvicto for the treatment of adult patients with advanced prostate cancer. ... Prostate cancer is the second leading cause of cancer-related death in

Latest news

More from news
Approximately 69 fully matching, plus 307 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    continuum of targeted therapies now available to prostate cancer patients, including PARP inhibitors. ... Similarly, DRD testing in late stage prostate cancer is needed to identify patients who could potentially benefit from PARP inhibition.

  • Why digital is the solution to the healthcare crisis Why digital is the solution to the healthcare crisis

    Be it treatment for cancer, aches and pains, unusual lumps, headaches – the general malay that you would visit your doctor or hospital for consultation and treatment. ... Nudge behaviour, such as timely reminders for breast or prostate cancer screening,

  • The human connection: how to achieve emotive creativity in pharma The human connection: how to achieve emotive creativity in pharma

    your patients a disservice while you’re at it). We’ve been acutely aware of this balancing act in our own work; a recent film we worked on for prostate cancer ... With this as our starting point, we introduced messaging about the importance of

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon

More from intelligence
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 6 fully matching, plus 20 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....